文献速递其他结缔组织病

抑制I型干扰素受体通路可改善皮肌炎血清诱导的肌无力

Inhibition of the type I interferon receptor pathway protects against muscle weakness induced by dermatomyositis serum.
PubMed 文献 · Ann Rheum Dis · 2026-03-17

该研究将健康小鼠趾短屈肌与10%健康血清或皮肌炎患者血清(n=9)共孵育24小时,发现皮肌炎血清可导致显著肌力下降,而IFNAR1抗体或ruxolitinib可消除该效应,提示I型干扰素信号通路是皮肌炎肌无力的重要致病因素。

要点

  • 皮肌炎患者血清可诱导健康小鼠肌肉出现显著肌力下降。
  • IFNAR1抗体或ruxolitinib可消除皮肌炎血清诱导的肌无力效应。
  • 血源性因子通过I型干扰素信号通路参与皮肌炎肌肉病变。

核心结论

  • 皮肌炎患者血清中的因子可激活骨骼肌I型干扰素信号通路,构成肌无力的重要致病因素。
  • 靶向IFNAR1信号通路的药物干预具有治疗皮肌炎肌无力的潜力。

研究设计与样本

  • 离体实验:健康小鼠趾短屈肌与10%健康血清或皮肌炎患者血清(n=9)孵育24小时。
  • 使用IFNAR1抗体或JAK-STAT抑制剂ruxolitinib调节干扰素信号。
  • 进行RNA测序及生物信息学分析以识别差异表达基因和IFN相关通路。

主要发现

  • 皮肌炎血清(而非健康对照血清)孵育导致显著肌力下降。
  • 生物信息学分析显示IFNAR1抗体下调I型干扰素诱导基因。
  • 通路分析显示多个干扰素相关通路富集。
  • IFNAR1抗体或ruxolitinib均消除皮肌炎血清诱导的效应。

临床怎么用

  • 提示I型干扰素受体通路可能是皮肌炎肌无力的治疗靶点。
  • ruxolitinib及IFNAR1抗体在离体模型中显示保护作用,支持进一步临床研究。

局限性

  • 样本量较小(皮肌炎血清n=9)。
  • 仅为离体小鼠肌肉实验,结论需在体内及临床研究中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Dermatomyositis (DM) is characterised by systemic inflammation, debilitating muscle weakness, cutaneous lesions, and increased mortality. An upregulation of type I interferon (IFN)-stimulated genes is observed in patients with DM. However, it remains unclear whether type I IFNs cause muscle weakness in DM. This study aimed to investigate the role of IFN-α/β receptor signalling in muscle weakness induced by factors in DM serum. METHODS: In ex vivo experiments, flexor digitorum brevis muscles were isolated from healthy mice and incubated 24 hours with 10% healthy serum or serum from patients with DM (n = 9). To modulate IFN signalling, an antibody against the type I IFN receptor α/β subunit 1 (IFNAR1) or the Janus kinase-signal transducer and activator of transcription inhibitor ruxolitinib was used. RNA sequencing, followed by bioinformatics analysis, was conducted to identify differentially expressed genes and affected pathways related to IFN signalling. RESULTS: Incubation with serum from patients with DM, but not that from healthy controls, caused significant muscle weakness manifested by a reduction in muscle force. Bioinformatic analyses revealed downregulation of type I IFN-inducible genes with IFNAR1 antibody. Pathway analysis showed enrichment of several IFN-related pathways. Inhibition of type I IFN signalling with either an IFNAR1 antibody or ruxolitinib abolished DM serum-induced effects. CONCLUSIONS: Factors in serum from patients with DM can activate the type I IFN signalling pathway in skeletal muscles, which constitutes an important causal factor for muscle weakness. Our data support a mechanistic model where blood-borne factors contribute to muscle disease phenotypes and underscore the therapeutic possibilities of pharmacological interventions targeting the IFNAR1 signalling pathway.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Kaewin S, Leijding C, Gastaldello S, et al. Inhibition of the type I interferon receptor pathway protects against muscle weakness induced by dermatomyositis serum. Ann Rheum Dis. 2026. PMID: 41850941. doi:10.1016/j.ard.2026.02.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。